BEGIN:VCALENDAR VERSION:2.0 PRODID:-//hacksw/handcal//NONSGML v1.0//EN BEGIN:VEVENT UID:cf0663914f2488af520a8ec5923ef207 DTSTAMP:20260604T040202Z DTSTART:20210331T130000 DTEND:20210331T140000 SUMMARY:New single-dose HPV vaccination evidence and resources DESCRIPTION:The Single-dose HPV Vaccine Evaluation Consortium collates and synthesizes existing evidence and evaluates new data on the potential for single-dose HPV vaccination. Their goal is to inform global policy discussions and program guidance, as well as to raise awareness and understanding of its implications. The Consortium invites you to join a webinar with some of their researchers to review the recently released evidence.\n\nThe 31 March session (3-4 PM CET) will provide updates from clinic trials, observational studies, and modeling analyses on the efficacy, immunogenicity, effectiveness, and cost-effectiveness of single dose HPV vaccination. If demonstrated to be effective, single-dose HPV vaccination could facilitate new options for current national programs by simplifying delivery and lowering program costs. For low- and middle-income countries that have delayed introducing HPV vaccines because of financial, logistical or other barriers; a single-dose HPV vaccination schedule could accelerate introduction of HPV vaccines into national immunization schedules. \n\nPresenters\n\nKiesha Prem, PhD, Research Fellow, Centre for the Mathematical Modelling of Infectious Diseases, LSHTM \n\nAnne Schuind, MD, Initiative Team Leader for HPV Vaccines, Center for Vaccine Innovation and Access, PATH\n\nEvan Simpson, DrPH, MPH, Team Lead, Vaccine Implementation, Center for Vaccine Innovation and Access, PATH\n \nRegister here: https://who.zoom.us/webinar/register/WN_TdCbMNe0S-malQ_I0dZQ_w\n \nFor resources or to discuss about this topic: https://www.technet-21.org/en/forums/discussions/technet-webinar-new-single-dose-hpv-vaccination-evidence-and-resources X-ALT-DESC;FMTTYPE=text/html:\n\n\n\n\n\n\n\n\n

The Single-dose HPV Vaccine Evaluation Consortium collates and synthesizes existing evidence and evaluates new data on the potential for single-dose HPV vaccination. Their goal is to inform global policy discussions and program guidance, as well as to raise awareness and understanding of its implications. The Consortium invites you to join a webinar with some of their researchers to review the recently released evidence.

The 31 March session (3-4 PM CET) will provide updates from clinic trials, observational studies, and modeling analyses on the efficacy, immunogenicity, effectiveness, and cost-effectiveness of single dose HPV vaccination. If demonstrated to be effective, single-dose HPV vaccination could facilitate new options for current national programs by simplifying delivery and lowering program costs. For low- and middle-income countries that have delayed introducing HPV vaccines because of financial, logistical or other barriers; a single-dose HPV vaccination schedule could accelerate introduction of HPV vaccines into national immunization schedules.

Presenters

Kiesha Prem, PhD, Research Fellow, Centre for the Mathematical Modelling of Infectious Diseases, LSHTM

Anne Schuind, MD, Initiative Team Leader for HPV Vaccines, Center for Vaccine Innovation and Access, PATH

Evan Simpson, DrPH, MPH, Team Lead, Vaccine Implementation, Center for Vaccine Innovation and Access, PATH

For resources or to discuss about this topic: https://www.technet-21.org/en/forums/discussions/technet-webinar-new-single-dose-hpv-vaccination-evidence-and-resources

\n\n\n LOCATION: END:VEVENT END:VCALENDAR